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Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting joints, and it
may manifest as peripheral arthritis, dactylitis, enthesitis, spondylitis, or sacroiliitis.
In the great majority of patients, PsA is accompanied by the most frequent
psoriatic manifestation—psoriasis vulgaris. The major genetic risk factor for PsA is
an HLA-C allele, and in recent genome-wide association studies few other
susceptibility loci have as yet been identified. In this issue, Murdaca et al. (2014)
describe an association of an intronic single-nucleotide polymorphism at the TNF
locus (þ 489) with PsA, disease severity, and treatment responses to tumor
necrosis factor-a blockers.
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With an increase in the therapeutic
armamentarium for chronic inflamma-
tory diseases, there is much interest in
predicting the therapy best suited to an
individual patient in order to achieve the
best therapeutic result, as well as to
avoid costs and side effects. In clinical
trials for psoriatic arthritis (PsA), tumor
necrosis factor-a (TNF-a) blockers have
been shown to have excellent clinical
efficacy and to prevent further structural
damage to joints. However, the reasons
why 30–60% of patients do not respond
sufficiently to treatment with TNF-a
blockers (as measured by a failure to
achieve an ACR20 response after 12–16
weeks of treatment) are largely
unknown. Different combinations of
genetic factors are assumed to have a
role. In this issue, Murdaca et al., 2014
report preliminary evidence for an
association between the single-
nucleotide polymorphism (SNP) þ489
at the TNF locus and both susceptibility
to the development of PsA and to
treatment responses to TNF-a blockers.
Experience with other drugs has
exemplified the potential of genetic
predictors in the use of drug therapies.
Good predictors of therapeutic response
are found in tumor therapy, in which the
presence of somatic mutations in
tumors—responsible for dysregulation
of cell growth and/or cell survival—
may also predict responses to drugs
tailored to impact the corresponding
signal transduction pathways. For exam-
ple, in metastatic melanomas, tumors
with the activating BRAF mutation
V600E respond to the BRAF inhibitors
vemurafenib or dabrafenib in about
50% of patients, whereas these drugs
are ineffective in patients without muta-
tions at V600 (Jang and Atkins, 2014).
These findings are reflected in the
drugs’ license, which excludes patients
whose tumors do not carry BRAF
mutations at V600.
In contrast, for germline mutations,
predictive value has been established
primarily for side effects of drugs. For
example, for carbamazepine, severe
drug reactions, such as Stevens-Johnson
syndrome/toxic epidermal necrolysis,
have been associated with HLA-
B*1502. The odds ratio for the occur-
rence of carbamazepin-induced Ste-
vens-Johnson syndrome/toxic epidermal
necrolysis in carriers of HLA-B*1502 is
high: 236 (95% confidence interval 72–
778) in a meta-analysis of several Chi-
nese populations (Yip et al., 2012).This
finding has been translated into a
recommendation by the US Federal
Drug Administration to test for this
MHC allele in patients of certain an-
cestry who are more likely to carry HLA-
B*1502 (for example, Han Chinese,
Hong Kong Chinese, and patients of
Thai origin). For these carriers,
carbamazepine should be used only if
benefits clearly outweigh the risk.
There is high linkage
disequilibrium within
the densely packed
genomic region at
chromosome 6p21.3.
When investigating genetic variations
as predictors of therapeutic efficacy in
complex diseases, the candidate gene
approach is selected most commonly.
Obvious candidate genes include
genetic variations associated with the
disease, as well as variations in genes
that code for molecules involved in the
pathway targeted by the drug. For TNF,
the candidate gene chosen by Murdaca
et al. (2014) in this issue, both condi-
tions hold true. The authors describe a
trend for a higher frequency of the TNF
SNP þ489G allele in responders to
etanercept therapy compared with non-
responders, but not in patients treated
with adalimumab, in whom, by con-
trast, the genotype SNP þ489AA was
more frequent. It might be expected that
the genetic bases of treatment responses
are similar for all of the TNF-a blockers;
however, molecular differences may
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explain some of the differences in thera-
peutic responses, and possibly genetic
predispositions. This holds true especi-
ally for differences between the fusion
protein etanercept on the one hand and
the mAbs adalimumab and infliximab
on the other. Etanercept is a fusion
protein that binds lymphotoxin-a (also
termed TNF-b) in addition to TNF-a.
Also, there are differences in pharma-
codynamics between the mAbs and
etanercept: in contrast to infliximab
and adalimumab, etanercept is belie-
ved to bind only soluble and
membrane-bound TNF trimers, but
not monomers and dimers, and it does
not appear to fix complement. This has
led to the speculation that etanercept—
as opposed to adalimumab and
infliximab—is unlikely to form aggre-
gates on the surface of TNF-producing
cells, which ordinarily would activate
complement-dependent lysis and
antibody-dependent cell-mediated cyto-
toxicity (Furst et al., 2006). The search
for genetic variations influencing thera-
peutic efficacy, however, may also be
influenced by factors not related
primarily to the mode of a drug’s
effect. An important mechanism for
treatment failure of biologics is the
formation of anti-drug antibodies. Even
so-called ‘‘humanized’’ therapeutic
antibodies—not containing any murine
parts—may be recognized as ‘‘non-self’’
proteins. Thus, some anti-drug antibo-
dies can neutralize the target drug and
prevent therapeutic effects. Such anti-
bodies can often be detected within the
first 28 weeks of treatment in patients
treated with adalimumab or infliximab,
and they are associated with lack of
efficacy. In case of adalimumab, they
have been observed in up to 53% of
patients (van Schouwenburg et al.,
2013). In contrast, antibodies against
etanercept do not neutralize the drug’s
effect and thus do not lead to treatment
failure. Thus, anti-drug antibodies are
relevant for infliximab and adalimumab
but not for etanercept. Formation of
anti-drug antibodies in itself may vary
between carriers and non-carriers of cer-
tain genetic factors, and these factors
may also contribute to genetically based
lack of efficacy. Interestingly, a recent
large multinational genome-wide asso-
ciation study analyzing anti-TNF-a drug
responses in 2,703 patients with
rheumatoid arthritis, using a multistep
strategy, did not reveal an association
between variants of TNF and treatment
responses (Umicevic et al., 2013).
Subgroup analyses for treatment
with different TNF-a blockers in that
study were not pursued (Umicevic
et al., 2013).
From the genetic point of view, PsA
belongs to the category of ‘‘complex’’
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Figure 1. Upper part: Genomic arrangement of genes on chromosome 6p21.3. Thicker sections of the horizontal line represent the genes for coiled-coil helical
rod protein 1 (CCHCR1), HLA-C, and tumor necrosis factor (TNF). Large solid boxes represent exons, and small solid boxes represent the 30-untranslated
region (30-UTR) or 50-UTR. Arrowheads represent the orientation of the genes. Vertical bars indicate 7 of the 8 relevant single-nucleotide polymorphisms (SNPs),
which are located at CCHCR1 (n¼2), and TNF promoter and first intron (n¼ 5). Arrows in the middle part indicate correlations of relative positions of SNPs
between the upper and lower parts of the figure. Lower part: Linkage disequilibrium (LD) structure of the PSORS1 risk haplotype as defined by Huffmeier et al.
(2009) and of selected SNPs at the TNF locus in 226 PsA patients analyzed as described previously (Reich et al., 2007). Genotypes of intronic variant at þ 489
were determined in a genome-wide association study published previously (Huffmeier et al., 2010). (a) Physical relationship of variants, (b) name of selected
variants, and (c) pairwise LD plot of the PSORS1 risk haplotype and selected SNPs (illustrated by Haploview (Barrett et al., 2005). Each square plots the level of LD
between a pair of sites in the region; comparisons between neighboring sites lie along the first line. Black color indicates strong LD, gray indicates intermediate or
uninformative LD, and white indicates weak LD. The black triangle indicates neighboring SNPs within an LD block.
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diseases: an individual carrying several
genetic risk factors develops the disease
under the additional influence of (an)
environmental risk factor(s). PsA’s main
genetic risk factor is an HLA-C allele
(HLA-Cw*06), explaining a consider-
able portion of heritability in PsA and
even more in psoriasis vulgaris. In many
independent candidate association stu-
dies followed by genome-wide
approaches performed in PsA/psoriasis,
this genetic risk factor has almost always
been recognized as a major factor: (a)
by genome-wide linkage studies as
PSORS1 (psoriasis susceptibility locus
1) or (b) by genome-wide association
studies as a very defined association
signal at the HLA-C/HLA-B locus.
According to the current state of
knowledge, 144 variants are disease-
causing candidates, and, because of
the location of a subset in an enhancer
element, an influence on the expression
of the HLA-C risk allele is suspected
(Clop et al., 2013). However, the exact
mechanism by which HLA-Cw*06 or
other highly significantly associated
HLA-C/HLA-B risk alleles and/or haplo-
types (Chandran et al., 2013) contribute
to PsA and psoriasis remains to be
elucidated.
In the past era of candidate gene
studies, psoriasis vulgaris, but also PsA,
has been independently associated with
variants in the promotor region of the
TNF gene coding for TNF-a (Reich et al.,
2007; Giardina et al., 2011). As TNF is
known to locate quite closely to
the MHC at chromosome 6p21.3
(Figure 1a), it could be shown that
association of the promotor variant at
 238 is dependent on carriage of the
HLA-C risk allele; the latter was more
significantly associated with psoriasis
and PsA and therefore the more prob-
able disease-causing risk factor (Reich
et al., 2007). This dependence is
referred to as linkage disequilibrium. In
contrast, the promotor variant at 857
was associated with PsA independently
from carrier status of HLA-Cw*06.
Interestingly, current data provide
evidence that the promotor variant at
 857 is in strong linkage disequi-
librium to variant þ489 (r2¼0.98,
Figure 1b). Therefore, both variants at
the TNF locus, or perhaps their combi-
nation, are candidate variants. There is a
high linkage disequilibrium within the
densely packed genomic region at chro-
mosome 6p21.3. Therefore, an isolated
candidate approach at the TNF locus,
without considering linked risk alleles,
might lead to false-positive associations
(Daly and Day, 2001). In this respect, it
has been shown that the rarer allele of
intronic variant þ489 at TNF is also in
linkage disequilibrium with certain
HLA-B and HLA-D alleles (Low et al.,
2002). Therefore, the association of
intronic variant þ 489 with PsA suscep-
tibility and better responses to TNF
blockage in PsA is interesting (Murdaca
et al., 2014), although there is as yet
no evidence for a causal relationship.
More comprehensive genetic studies are
necessary to dissect the responsible
candidate variants. A functional valida-
tion of the latter could then provide a
biological link.
Possibly in the future, large consor-
tiums will be formed to investigate
genetic predictors of therapeutic
response to therapies in PsA, analogous
to those investigating the genetic basis
of the disease. The potential of saving
costs of therapies likely to be ineffective
or not tolerated by patients—in addition
to a desire to provide the optimal
therapy for an individual patient—may
be sufficient incentive for governmental
agencies to support such research.
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